

## **Supplementary Material**

### **A $\beta$ -dependent and independent genetic pathways regulating CSF tau biomarkers in Alzheimer's disease**

Atul Kumar, PhD<sup>1</sup>; Shorena Janelidze<sup>1</sup>; Erik Stomrud, MD, PhD<sup>1, 2</sup>; Sebastian Palmqvist, MD, PhD<sup>1, 2</sup>; Oskar Hansson, MD, PhD<sup>1, 2, #</sup>; Niklas Mattsson-Carlsson, MD, PhD<sup>1, 3, 4, #</sup>

<sup>1</sup>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden

<sup>2</sup>Memory Clinic, Skåne University Hospital, Malmö, Sweden

<sup>3</sup>Department of Neurology, Skåne University Hospital, Lund, Sweden

<sup>4</sup>Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden

# Shared Senior Authors

#### **Email Addresses**

Atul Kumar: atul.kumar@med.lu.se


Shorena Janelidze: shorena.janelidze@med.lu.se

Sebastian Palmqvist: sebastian.palmqvist@med.lu.se

Erik Stomrud: erik.stomrud@med.lu.se


Oskar Hansson: oskar.hansson@med.lu.se

Niklas Mattsson-Carlsson: niklas.mattsson-carlsson@med.lu.se




**eFigure 1. Comparative results for associations between Polygenic Risk Scores (PRS) and CSF Aβ1-42 in BioFINDER (BF) and ADNI.** The x-axis represents the 7 different PRS models at different p-value thresholds based on the GWAS summary statistics (PRS1  $\leq$  0.05, PRS2  $\leq$  5e-3, PRS3  $\leq$  5e-4, PRS4  $\leq$  5e-5, PRS5  $\leq$  5e-6, PRS6  $\leq$  5e-7, PRS7  $\leq$  5e-8). The models were adjusted for age, gender, education, baseline MMSE, *APOE* ε2 and ε4 count, and the top 10 principal components (PC) from the principal component

analysis (PCA) on the entire set of genotype data. The y-axis shows the negative log of the p-value for the significance of associations between PRS models with different tau measures. The values on the top of each bar show the association's effect size (beta-coefficient). The horizontal dotted line shows the p-value threshold of 0.05. \*These PRSs were significant after Bonferroni-correction at p-value < 0.05.




**eFigure 2. Associations between significant Polygenic Risk Scores (PRS) and tau measures adjusted for CSF A $\beta$ 1-42 in ADNI.** The x-axis shows the different PRS models (this analysis only included models that were significantly associated with tau measures when not adjusted for CSF A $\beta$ 1-42). The models were adjusted for age, gender, education, baseline MMSE (not for the intercept), *APOE*  $\epsilon$ 2 and  $\epsilon$ 4 count, and the top 10 principal components (PC) from the principal component analysis (PCA) on the entire set of genotype data, as well as CSF A $\beta$ 1-42). The y-axis shows the negative log of the p-value for the significance of associations between PRS models with different tau measures. The values on the top of each bar indicate the association's effect size (beta-coefficient). The horizontal dotted line shows the p-value threshold of 0.05. \*These PRSs were significant after adjusted for CSF A $\beta$ 1-42 and Bonferroni-correction at p-value < 0.05.




**eFigure 3: Mediation analysis between PRS, A $\beta$  status and CSF P-tau181.**


Mediation analysis with PRS4 as a predictor of CSF P-tau181, mediated by A $\beta$  status. The figure includes the following standardized regression coefficients: a, the effect of PRS on A $\beta$ ; b, the effect of A $\beta$  on CSF P-tau181 level; c, the direct association between PRS and CSF P-tau181 level; c', the association between PRS and CSF P-tau181 level when adjusting for A $\beta$ ; and c-c', the mediated effect on CSF P-tau181 level.




**eFigure 4: Functional Enrichment analysis for the genes carrying the variants used for calculating PRS2.** Genes enriched for Gene Ontology (GO) Biological Process (BP) terms: The x-axis represents the significance of enrichment (Negative log of corrected p-value) for the gene set involved in each category term. The y-axis shows the respective category terms. The Enrichment factor for each enriched term is marked corresponding to each bar.



**eFigure 5: Functional Enrichment analysis for the genes carrying the variants used for calculating PRS2.** Genes enriched for KEGG pathway terms: The x-axis represents the significance of enrichment (Negative log of corrected p-value) for the gene set involved in each category term. The y-axis shows the respective category terms. The Enrichment factor for each enriched term is marked corresponding to each bar.



**eFigure 6: Functional Enrichment analysis for the genes carrying the variants used for calculating PRS2.** Genes enriched for the gene-disease association: The x-axis represents the significance of enrichment (Negative log of corrected p-value) for the gene set involved in each category term. The y-axis shows the respective category terms. The Enrichment factor for each enriched term is marked corresponding to each bar.



**eFigure 7: Functional Enrichment analysis for the genes carrying the variants used for calculating the A $\beta$ -dependent PRS (PRS2-R-Incl-19).**

Genes enriched for the gene-disease association. The x-axis represents the significance of enrichment (Negative log of corrected p-value) for gene set involved in category term. The y-axis shows the category terms. The Enrichment factor for each enriched term is marked corresponding to each bar.